![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00092170 |
The purpose of this study is to determine the effect of an approved medication for adults for an investigational use in pediatric patients 3 months to 17 years for the treatment of complicated intra-abdominal infections or acute pelvic infections.
Condition | Intervention | Phase |
---|---|---|
Infections Pelvic Infections |
Drug: MK0826, ertapenem sodium Drug: Comparator: Ticarcillin/Clavulanate |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Safety/Efficacy Study |
Official Title: | A Prospective, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Ertapenem Sodium ( MK0826) Versus Ticarcillin/Clavulanate in the Treatment of Hospital-Acquired Pneumonia, Complicated Intra-Abdominal Infections, and Acute Pelvic Infections in Pediatric Patients |
Ages Eligible for Study: | 3 Months to 17 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2004_062 |
Study First Received: | September 21, 2004 |
Last Updated: | October 8, 2007 |
ClinicalTrials.gov Identifier: | NCT00092170 |
Health Authority: | United States: Food and Drug Administration |
Intra-abdominal infections Acute pelvic infections |
Ertapenem Ticarcillin Clavulanic Acid |
Clavulanic Acids Pelvic Infection Pneumonia |
Anti-Infective Agents Anti-Bacterial Agents Communicable Diseases Molecular Mechanisms of Pharmacological Action |
Therapeutic Uses Enzyme Inhibitors Infection Pharmacologic Actions |